Essity announces price increases

PR Newswire

STOCKHOLM, April 7, 2021 /PRNewswire/ — Hygiene and health company Essity is announcing price increases in Consumer Tissue as a result of higher raw material costs. The price increases are announced in Essity’s key markets and the percentage increases are on average in the mid-to-high single digits.

In addition, Essity is preparing price increases in other product categories impacted by higher raw material costs.

NB:This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:50 CET on April 7, 2021. 

Karl Stoltz, Media Relations Manager, +46 8 788 51 55

For further information, please contact:

Per Lorentz, Vice President Corporate Communications, +46 8 788 52 51, [email protected]

Johan Karlsson, Vice President Investor Relations, +46 8 788 51 30, [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/essity/r/essity-announces-price-increases,c3320141

The following files are available for download:


https://mb.cision.com/Main/15798/3320141/1398013.pdf

Essity announces price increases

 

Cision View original content:http://www.prnewswire.com/news-releases/essity-announces-price-increases-301263831.html

SOURCE Essity

Proactive news headlines including Alta Zinc, Auteco Minerals, Perseus Mining and K2fly

Sydney, April 07, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

  • Alta Zinc Ltd (ASX:AZI) (FRA:8EE) has received thick, high-grade zinc and lead results from the first drill pad of its maiden drilling program at Ponente area of the Gorno Project in Italy with added silver. Click here
  • Auteco Minerals Ltd’s (ASX:AUT) (OTCMKTS:MNXMF) strategy to upgrade and grow the 1-million-ounce inferred resource at its Pickle Crow Gold Project in Canada continues to deliver strong results with the discovery of more high-grade mineralisation. Click here
  • Perseus Mining Ltd (ASX:PRU) (TSE:PRU) (OTCMKTS:PMNXF) (FRA:P4Q) has demonstrated potential for organic growth of gold inventories across its multi-mine asset portfolio in Côte d’Ivoire with further broad high-grade results from regional drilling at Sissingué and Yaouré. Click here
  • K2fly Ltd (ASX:K2F) experienced a record invoicing quarter, with A$2.06 million in invoices raised in the March quarter, a 28% increase on the A$1.61 million of the corresponding quarter of FY20. Click here
  • Miramar Resources Ltd (ASX:DRM) has kicked off drilling at its highly prospective gold projects in world-class locations and is progressing various other projects through permitting and or tenement grant. Click here
  • CV Check Ltd (ASX:CV1) has completed the acquisition of CI6 Pty Ltd an entity that owns Bright People Technologies Pty Ltd (BPT), a SaaS cloud-based provider of workforce credentials and compliance software through the Enable and Cited brands. Click here

About Proactive  

With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors.

Proactive’ s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally.

Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

•           Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.
•           We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate.
•           We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy.
•           Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting.
•           We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.

For more information on how Proactive can help you make a difference, email us at [email protected]



Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines  

  • Launch of a new and more impactful global corporate social responsibility strategy
  • Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion
  • Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines

PARIS – April 7, 2021 – In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. Embedded in Sanofi’s long-term strategy, the company’s commitment is based on four essential pillars in which Sanofi is uniquely positioned to make a difference: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees.

“The pandemic has forced us to question nearly every aspect of our lives: how we live and work, and how we connect with our communities and the planet. Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory,” said Hudson. “This unique context led us to elevate our ambition for our Corporate Social Responsibility strategy and embed it even more into our mission to transform lives and our vision for a better future.”

Sanofi Global Health, pillar of access to essential medicines

A cornerstone of Sanofi’s CSR strategy, Sanofi Global Health is a newly formed nonprofit unit within the company. Leveraging the company’s diverse and large portfolio of medicines and global footprint, Sanofi Global Health is dedicated to increasing access to medicines considered essential by the World Health Organization (WHO) for patients in 40 lower income countries. Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. Sanofi Global Health will also fund the training of healthcare professionals or the set up and development of sustainable care systems for those who suffer from chronic diseases and require complex care.

Sanofi Global Health is the first global initiative to provide access to such a broad portfolio of medicines, in so many countries and across several therapeutic areas, while funding local support programs.

Additionally, Sanofi is committed to helping 1,000 patients living with rare diseases who have no access to treatments and will donate 100,000 vials of medicine for their treatments each year. This continues Sanofi’s 30-year commitment to patients suffering from rare diseases, such as Fabry, Gaucher or Pompe diseases, for which access to treatment is often limited.

Leveraging R&D efforts to address crucial treatment gaps

Sanofi continues to support vulnerable communities and commits to developing innovative medicines for pediatric cancer, with the ultimate ambition of eliminating cancer deaths in children. In low- to middle-income countries, a child is four times more likely to die of pediatric cancers than children living in high-income countries.

Sanofi also continues its efforts to fight polio and sleeping sickness, two of its historical programs that address global health issues. In December 2020, Sanofi announced it had renewed its five-year partnership with WHO to fight neglected tropical diseases that affect approximately one billion people. In this context, Sanofi, the only pharmaceutical company that keeps developing and supplying treatments for African trypanosomiasis or sleeping sickness, has committed itself alongside the WHO to eliminate this neglected tropical disease in humans by 2030. For 40 years, Sanofi has supplied billions of polio vaccine doses, including hundreds of millions of donated doses to support the global polio eradication effort.

Zero plastic packaging for vaccines and ecodesign of products

For several years, Sanofi has been implementing a global environmental protection program, Planet Mobilization. Today, the company is amplifying its actions to further improve the environmental footprint of its products and activities.

To reduce its greenhouse gas emissions by 55% by 2030 and contribute to better resource conservation, Sanofi plans to remove all pre-formed plastic packaging (blister packs) for its vaccines by 2027. The company is also committed to ecodesigning all its new products by 2025. In terms of energy management, all Sanofi sites will use 100% renewable electricity and the company has set a target of a carbon-neutral car fleet, both by 2030.

Pushing to build more diverse and inclusive workforce

As a global company, Sanofi is committed to ensuring that its leaders reflect the communities and patients it serves. The company is committed to building an organization where all employees have equal opportunities to reach positions of responsibility within the company. Sanofi will continue to build a workforce that is fully reflective of the communities employees live in and the patients the company serves. This element of the social impact strategy will be integrated into the career development of Sanofi leaders worldwide, ensuring a mindset that fosters diversity and inclusion throughout the company.
             

“Throughout this pandemic, public authorities, scientists, and industry have worked closely together to discover and produce vaccines at a pace that has defied historical precedent. We now have to apply this same sense of urgency to other pressing threats, such as climate change, and issues that the pandemic has sharply put into focus, including widening racial and healthcare inequalities. Let’s always remember that crises do not just neatly follow one after the other, they stack up. At Sanofi, we know we can do more,” said Hudson.

 

About Sanofi

 

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

 

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

 

Sanofi, Empowering Life

 


Media Relations Contact

Ashleigh Koss
Tel: +1 (908) 981-8745
[email protected]

 

Sandrine Guendoul
Tel.: +33 (0) 6 25 09 14 25
[email protected]

 

 

 

Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine

 

Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco

 

IR main line:
Tel.: +33 (0)1 53 77 45 45
[email protected]

 

https://www.sanofi.com/en/investors/contact

 

 

Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing  could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements

 

 


 

 

Attachment



Reliq Health Technologies, Inc. Announces New Contract with Orthopedic Practice in Texas

HAMILTON, Ontario, April 07, 2021 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed a new contract with its first Orthopedic Practice in Texas and, in response to significant market demand, has expanded its iUGO Care platform to allow Orthopedic Specialists to manage their chronic orthopedic and post-operative patients at home.

“As the vaccine rollout successfully proceeds in the United States, we are very pleased to see our clients moving forward with patient onboarding at a steadily increasing pace,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “Now that clinicians in the US are able to return their focus to proactive patient care, we’re experiencing significant new demand for deployment of our existing solutions as well as requests for new features. We are excited to launch our newest iUGO Care module, designed to support Orthopedic Specialists who want to monitor both their chronic patients (e.g. those living with rheumatoid arthritis, osteoarthritis, osteoporosis, etc.) and their post-operative patients at home. According to the CDC, there are over 5.7 Million arthritis patients in Texas alone, representing a large and growing new target market segment for Reliq. Using iUGO Care to provide Remote Patient Monitoring (RPM), Chronic Care Management (CCM), Principal Care Management (PCM) and Behavioural Health Integration (BHI) services to chronic orthopedic patients can help improve medication adherence, increase compliance with prescribed physiotherapy exercises and reduce the depression and anxiety often seen in chronic pain patients, significantly enhancing their quality of life.”

Leveraging the existing Medicare and Medicaid billing codes, Orthopedic practices can generate over $500,000 per year in new billings by providing RPM, CCM, PCM and BHI services to their patients. Reliq expects to begin onboarding orthopedic patients under this contract in April, at an average revenue of $50 USD per patient per month.

Reliq Health

Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director

For further information please contact:

Company Contact

Investor Relations at [email protected]

US Investor Relations Contact

Investor Relations
Lytham Partners, LLC
Ben Shamsian
New York | Phoenix
646-829-9701
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company“) does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.

 



Clarity Gold Mobilizes Second Rig for Ongoing Drill Program in Quebec

VANCOUVER, British Columbia, April 07, 2021 (GLOBE NEWSWIRE) — Clarity Gold Corp. (“Clarity” or the “Company”) (CSE: CLAR, OTC: CLGCF, FSE: 27G) is pleased to report that it has begun mobilizing a second drill rig to the Destiny Project in the Abitibi. The rig will commence operations at the GAP Zone, a coarsely drilled zone along strike and east of the DAC Zone. The drill will be tasked with completing several holes designed to infill historic drilling and test the GAP Zone at depth. Salient results from previous drilling in the GAP Zone include 16.1 g/t Au over 6 m from 85.5 m including 90.3 g/t Au over 1 m.

“We are very excited to bring a second drill rig into our ongoing program,” said James Rogers, CEO of Clarity. “As exploration progresses, the addition of the second drill rig will increase efficiency allowing the company to more rapidly complete the planned program.”

About the Destiny Project

  • Option to acquire 100% ownership.
  • Located in the historic, mineral rich Abitibi Greenstone Belt.
  • Gold mineralization occurs in high-grade quartz veins within shear zones starting at 15 m below surface.
  • Drilling results include:

    • 167 g/t Au over 1 m (from 221.7 m)
    • 6.15 g/t Au over 23.6 m (from 117.2 m)
    • 19.49 g/t Au over 2.7 m (from 166.0 m)
  • The Historical Estimate at the DAC Zone is open along strike with only coarse drilling denoting high grade intercepts outside of the 2011 Historical Estimate area showing expansion potential along strike from the DAC Zone over approximately 2.5 km to the Darla Zone.
  • Excellent infrastructure – ~75 km NNE of Val d’Or with road access.
  • Considerable work done historically including over 50,000 m of diamond drilling.

The Destiny Project is located in the prolific Abitibi Greenstone Belt where more than 190 million ounces of gold have been produced historically along major structural breaks within the assemblage of Archean-age volcanic, sedimentary and intrusive rocks. The Destiny Project lies along the approximately 400 km long Chicobi Deformation Zone, a major structural break which is largely underexplored in the Abitibi Greenstone Belt.

The 5,013 ha project includes the DAC Zone, one of several gold zones along an approximately 6 km long segment of the Despinassy Shear Zone within the Chicobi Deformation Zone. Approximately 2.5 km east along strike of the DAC Zone is the Darla Zone. In between the Darla and DAC is the coarsely drilled GAP zone where 2012 drilling intercepted anomalous gold in all 12 holes which were spaced 100 m apart.

The current exploration potential is based on decades of past work on the Destiny Project. Exploration of the Destiny Project dates back to the 1930s. The first concerted diamond drilling campaign commenced in 1998.

Previous work on the property can be summarized as follows:

  • 172 Diamond drill holes comprising approximately 50,400 m
  • Reconnaissance till sampling from 11 Sonic drill holes
  • 2,430 MMI geochemical samples
  • 982 line km of airborne VTEM surveys
  • 171 line km of ground magnetics surveys
  • 128 line km of IP

Qualified Person

Mr. Rory Kutluoglu P. Geo., a member of the advisory board and a consultant of the Company, is the Qualified Person (“QP”) under NI 43-101 for the technical information in this news release and has verified the data disclosed for the Destiny Project and approves the technical contents contained in this news release.

About Clarity

Clarity Gold Corp. is a Canadian mineral exploration company focused on the acquisition, exploration and development of gold projects in Canada. The Company has entered into an option agreement to purchase 100% of the Destiny Project, Clarity’s flagship asset, a gold-focused project in the mineral rich Abitibi region in Quebec. The Company is based in Vancouver, British Columbia, and is listed on the CSE under the symbol “CLAR”. To learn more about Clarity Gold Corp. and its projects please visit www.claritygoldcorp.com.

ON BEHALF OF THE BOARD

James Rogers
Chief Executive Officer
Tel: 1 (833) 387-7436
Email: [email protected] 
Website: claritygoldcorp.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: that the first drilling will confirm historic drilling results and provide continuous assays across the mineralized zone where previous drilling only sampled specific intervals; that the drilling will extend mineralization to depth in the DAC zone and along the Gap and Darla Zones; and that the Company will complete the planned initial 10,000m drilling program.

The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: that the drilling may not go as planned or start when expected; that the Company may experience difficulties in drilling and carrying out related work; changing costs for mining and processing; increased capital costs; the timing and content of upcoming work programs; geological interpretations based on drilling that may change with more detailed information; the risk that the Company may lose access to the property; the risks that the Company may not find any minerals in commercially feasible quantities; that the Company may not raise enough money to fund its exploration plans; uncertainty of development plans and cost estimates; commodity price fluctuations; political or economic instability and regulatory changes; currency fluctuations; the state of the capital markets; uncertainty in the measurement of mineral reserves and resource estimates; the Company’s ability to attract and retain qualified personnel and management; potential labour unrest; uncertainty as to reclamation and closure requirements for its mineral properties; unpredictable risks and hazards related to the exploration and development and operation of a mine or mineral property that are beyond the Company’s control; and other risks and uncertainties identified under the heading “Risk Factors” in the Company’s continuous disclosure documents filed on SEDAR. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.



Agillic launches a new fast and advanced SMS editor to help clients deliver personalised SMS experiences

Press release, Copenhagen, 7 April 2021

Danish omnichannel marketing automation software company Agillic supports its clients in delivering personalised communications. Product innovations, such as Agillic’s advanced SMS editor with an improved user interface and powerful features, help clients tap more smoothly into the benefits of personalised SMS experiences.

Nils Budde, Head of Products at Agillic, notes an increased interest in personalised SMS marketing among the company’s clients:

“We are experiencing massive traction towards sending out personalised SMS communication. Across industries, our clients report substantial payback from their SMS activities. While SMS has always had an unsurpassed opening rate, personalised SMS experiences send conversion rates – and value – steeply upward. Further, when SMS marketing is part of the overall omnichannel marketing strategy, like the one facilitated by the Agillic platform, clients can leverage attractive channel synergies.”

To spur the development further and gain a competitive edge, Agillic recently launched a new and advanced version of its SMS editor. The SMS editor offers an improved user interface making it faster and easier to set up personalised SMS communication, and is expected to attract new clients and contribute to an uplift in existing clients’ engagement.

Nils Budde continues:
“Working in the Agillic platform should be easy and intuitive, and we strive to remove any friction from the user interface. At the same time, we don’t want to compromise on advanced features, as illustrated by the new version of the SMS editor. Features such as dynamic content for personalisation, language versions, external links, preview, character count and more may seem trivial. But they are powerful features that make up a fast and advanced SMS editor with an optimal user experience – and at the end of the day, they contribute to successful strategy execution.”

The Retail and NGO & Charity sectors spearhead the development

Email is still the most prominent channel in terms of volume, and it accounts for a significant proportion of revenue contribution for brands. Compared to its potential, SMS marketing has been underutilised – but now it is picking up speed. It is becoming a vital channel in the omnichannel marketing strategy. Among Agillic’s clients, brands in the retail and the NGO & charity sectors are spearheading the development.

For example, the retail sector deploys SMS marketing to drive consumers to the website or the brick-and-mortar shops. In the NGO & Charity sector, SMS marketing is vital to fundraising, as it has an immediate and high conversion rate.

For the Danish Red Cross, speed matters

When a catastrophe occurs, humanitarian organisations and NGOs need to reach donors fast. Text messages are vital in this process, and the communication has to be set up and delivered within hours for maximum impact. Here, Agillic’s new SMS editor is making a tangible difference, according to Mikkel Wraae Hansen, Head of Individual Giving at Danish Red Cross:

“Speed matters when setting up and executing our SMS communication, both in times of crisis and in the general member communication. Texting accounts for a large part of our fundraising activities, and it is crucial and highly valuable that our staff is able to work as effectively as possible. The process, from setting up the SMS through testing and executing a personalised message, can be accomplished within a few hours – and we can reach our audience at an optimal time when they are most likely to respond.”

To learn more about how the Danish Red Cross is raising awareness and funds for their cause, please refer to the case story “Setting the cornerstone for omnichannel fundraising.”

For further information, please contact

Emre Gürsoy, CEO, Agillic A/S
+45 3078 4200
[email protected]

About Agillic A/S
Agillic is a Danish software company enabling marketers to maximise the use of data and translate it into relevant and personalised communication establishing strong relations between people and brands. Our customer marketing platform uses AI to enhance the business value of customer communication. By combining data-driven customer insights with the ability to execute personalised communication, we provide our clients with a head start in the battle of winning markets and customers.
Besides the company headquarter in Copenhagen, Agillic has sales offices in London (UK) and Stockholm (Sweden), as well as a development unit in Kyiv (Ukraine). For further information, please visit www.agillic.com

Agillic A/S Nasdaq First North Growth Market Copenhagen: AGILC

Masnedøgade 22 – Copenhagen – Denmark

                                                                                                                                                

 

Attachment



Dexcom Starts Direct Distribution in the Netherlands

Dexcom Starts Direct Distribution in the Netherlands

Dexcom is now directly selling the Dexcom G6 Continuous Glucose Monitoring (CGM) System across the Netherlands

  • Dexcom G6 CGM means no more fingersticks* for people with diabetes
  • Real-time glucose data sent wirelessly to a compatible smart device or Dexcom receiver
  • Customisable alerts and alarms for low and high glucose levels
  • Share glucose levels with up to five followers for additional remote monitoring

EDINBURGH, Scotland–(BUSINESS WIRE)–
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distribution collaboration with Zkope Healthcare and is now selling the Dexcom G6 CGM system directly throughout the Netherlands.

“At Dexcom, we are committed to expanding access to CGM for people with diabetes around the world. Being direct in market represents a significant step forward in allowing us to provide the best standard of care in diabetes management, bringing CGM technology to patients and healthcare providers across the Netherlands,” said Erik Bjorkman, general manager and senior vice president for EMEA at Dexcom.

Dexcom G6 uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a receiver or compatible smart device, enabling people with diabetes to receive real-time glucose data without the need of scanning or to prick their finger* . The system also offers customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events.

The Dexcom G6 app for compatible iOS and Android devices also allows users to share their glucose information with up to five followers, enabling family, loved ones and healthcare providers to remotely monitor them for extra peace of mind.

Dexcom G6 features at a glance:

  • Elimination of fingersticks or scanning for calibration and diabetes treatment decisions*
  • Continuous glucose readings sent automatically every five minutes via Bluetooth to any compatible smart device or to a Dexcom receiver
  • Customisable alerts and alarms, including a new Urgent Low Soon alert, which can warn users up to 20 minutes in advance of an urgent hypoglycemic event
  • Real-time data sharing with the Dexcom G6 app, allowing users to share their glucose data with up to five followers to monitor their glucose levels remotely for extra peace of mind
  • 10-day sensor allowing for longer wear than the previous generation Dexcom CGM
  • A slim, low profile transmitter for discreet wear
  • An auto-applicator designed to make sensor insertion simple with the touch of a button
  • A newly designed receiver with a touchscreen display (optional display device)
  • New sensor membrane that enables acetaminophen use without any effect on glucose readings§

The Dexcom G6 CGM system is indicated in the Netherlands for people with diabetes two years of age and older, including pregnant women. To learn more about Dexcom G6, visit www.dexcom.com or contact customer support by phone at 08000 201 985.

The Dexcom G6 received its CE Marking in June 2018, confirming that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC. The new system is the first CGM system to receive the US Food and Drug Administration’s (FDA) integrated (iCGM) classification. With this new classification, the Dexcom G6 CGM system is indicated for use as both a stand-alone CGM and for integration into automated insulin dosing (AID) systems.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

* If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

For a list of compatible devices, visit www.dexcom.com/compatibility.

Separate Follow app required.

§G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1,000mg every 6 hours. Taking a higher dose may affect the G6 readings.

© 2021 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. All rights reserved.

Media Contact:

Bijl PR, Melvin Voskuijl

Phone: +31 (0)10 284 29 29 / +31 (0)6 27 05 74 30

E-mail: [email protected]

KEYWORDS: Europe United Kingdom Netherlands

INDUSTRY KEYWORDS: Diabetes Health Medical Devices

MEDIA:

Logo
Logo

One Billion Additional Touch-free Visa Payments Made as Consumers Embrace Contactless Commerce

One Billion Additional Touch-free Visa Payments Made as Consumers Embrace Contactless Commerce

  • Less than a year since contactless limits increased across Europe, Visa has hit one billion additional touch-free transactions, 400 million of which took place in the UK.
  • Consumers and merchants are increasingly turning to contactless payments as a secure and seamless way to shop – two thirds (65%) of consumers say they would prefer to use contactless payments as much as, or more than, they do currently.
  • Contactless remains one of the most secure and convenient ways to shop with Visa following the limit increasing in some countries by as much as 50% last year, and the announcement that the UK contactless limit will increase to £100.

LONDON–(BUSINESS WIRE)–
Visa today announced that it has processed one billion additional touch-free payments1, where previously consumers would have needed to enter their PIN, as consumer confidence in contactless payments continues to grow. This milestone has been reached in less than a year since contactless payment limits were increased in 29 countries across Europe in response to the Covid-19 pandemic.

The growth of contactless payments has been a key trend during the pandemic, as touch-free payments have gone from being a convenience to a necessity for both consumers and retailers. Research from Visa shows that two-thirds (65%) of consumers globally would prefer to use contactless payments as much as, or more than, they are currently2.

Charlotte Hogg, Chief Executive Officer, Europe at Visa, commented: “The demand for touch-free payments indicates that contactless has become the norm for European consumers and retailers. Contactless payments are popular because they combine speed and convenience with security. Indeed, contactless cards experience among the lowest fraud rates of any payment type and in countries where contactless payments are widely used, fraud at the point of sale remains at historic lows.

“Today’s milestone demonstrates how consumers and retailers now rely on digital solutions to make everyday payments. Enabling contactless payments will be key to Europe’s economic recovery and while raising contactless limits alone won’t revitalise the European economy, it is a step in the right direction, giving consumers the confidence to spend, and providing shops, restaurants and other retailers a boost just when they need it most.”

Growing demand for contactless transactions is evident across Europe, with over 80% of in-store Visa payments now contactless3. In France and Germany, the number of contactless transactions has increased by two thirds and almost half respectively year-on-year4. Of the one billion transactions, 400 million took place in the UK5, and further growth can be expected given the announcement that the UK contactless limit will increase to £100 later this year.

The popularity of ecommerce is also surging across Europe, with over 15 countries experiencing a 40% or higher increase in ecommerce transactions in December 2020 versus the year before6.

With many businesses having to operate under restrictions and keep up with changing consumer behaviour, merchants are increasingly moving to online operations and embracing digital and contactless payments. Visa is working closely with its clients and partners to digitally enable over eight million small businesses across Europe, helping them adapt to enable customers to shop the way they want.

Contactless remains one of the most popular and secure payment methods for Visa customers and will be crucial to Europe’s economic recovery when restrictions lift and shops reopen.

– END –

About Visa

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit our website (www.visa.co.uk), blog (https://www.visa.co.uk/visa-everywhere/blog.html), and @VisaUK.

1 VisaNet data 

2 Visa Back to Business Study 2021 

3 VisaNet data 

4 VisaNet data 

5 VisaNet data 

6 VisaNet data

Ian Burge, Visa – [email protected]

Ellen Hodgetts, Grayling – [email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Finance Banking Professional Services Mobile/Wireless Technology

MEDIA:

BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

– Study explores potential in solid tumors and cutaneous T-cell lymphoma

– BI-1808 is one of three BioInvent drug candidates in clinical development

PR Newswire

LUND, Sweden, April 7, 2021 /PRNewswire/ — BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808.

“FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development,” said Martin Welschof, CEO of BioInvent.

The Phase I/IIa study will evaluate the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent, and in combination with the anti-PD-1 therapy Keytruda® in patients with ovarian cancer, non-small cell lung cancer and CTCL. It is planned to be carried out in the U.S., Denmark, Hungary, the United Kingdom and Russia and is already enrolling patients.

The anti-TNFR2 antibody BI-1808 is a first-in-class drug candidate and is part of BioInvent’s tumor-associated regulatory T cells (Treg)-targeting program. This has emerged from the F.I.R.S.T™ platform technology that simultaneously identifies new targets and high-quality antibodies, generating promising new drug candidates to target the tumor microenvironment (TME). TNFR2 is particularly upregulated on Tregs of the TME and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapies.

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:

Cecilia Hofvander                                          Mary-Ann Chang, LifeSci Advisors
Senior Director Investor Relations                +44 7483 284853
+46 (0)46 286 85 50                                      [email protected]
[email protected]               

BioInvent International AB (publ)

Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The information was submitted for publication at 08:30 a.m. CEST on April 7, 2021.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioinvent-international-ab/r/bioinvent-receives-ind-approval-for-phase-i-iia-trial-of-anti-tnfr2-antibody-bi-1808,c3320455

The following files are available for download:


https://mb.cision.com/Main/583/3320455/1397772.pdf

BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

 

Cision View original content:http://www.prnewswire.com/news-releases/bioinvent-receives-ind-approval-for-phase-iiia-trial-of-anti-tnfr2-antibody-bi-1808-301263794.html

SOURCE BioInvent

Notice of Annual General Meeting in LeoVegas AB (publ)

PR Newswire

STOCKHOLM, April 7, 2021 /PRNewswire/ — The shareholders of LeoVegas AB (publ), reg. no. 556830-4033, (the “Company“), are hereby convened to an annual general meeting to be held on Tuesday 11 May 2021.

Information with respect to Covid-19

The Company is mindful of the health and well-being of its shareholders and employees. It’s important for the Company to take a social responsibility and contribute to reduce the risk of transmission of the Covid-19. Due to the extraordinary situation the Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. Thus, it will not be possible to attend in person or through proxy at the annual general meeting.

Information on the decisions of the annual general meeting will be published as soon as the outcome of the advance voting is finally compiled on 11 May 2021.

Right to attend the Annual General Meeting and notice

Shareholders wishing to attend the Annual General Meeting must:

  1. on the record date, which is Monday 3 May 2021, be registered in the share register maintained by Euroclear Sweden AB;
  2. notify the participation at the general meeting no later than Monday 10 May 2021 by casting its advance vote in accordance with the instructions under the heading “Advance voting” below so that the advance voting form is received by Euroclear Sweden AB no later than that day.

Nominee registered shares

Shareholders, whose shares are registered in the name of a nominee, must temporarily register the shares in their own name at Euroclear Sweden AB. Shareholders whose shares are registered in the name of a nominee must, no later than on Monday 3 May 2021, via their nominee, temporarily register the shares in their own name in order to be entitled to participate at the general meeting. Voting registration requested by a shareholder in such time that the registration has been made by the relevant nominee no later than on Wednesday 5 May 2021 will be considered in preparations of the share register.

Proxy etc.

Shareholders who are casting advance  votes via proxy should submit a power of attorney, dated and signed by the shareholder, together with the advance vote. If the shareholder is a legal person, certificate of registration or other documents of authority shall be attached to the form. A form proxy will be available for downloading on the Company’s website www.leovegasgroup.com.

Advance voting

In view of the recent developments of the spread of Covid-19, the Company has taken certain precautionary measures in relation to the Annual General Meeting. The shareholders may exercise their voting rights at the general meeting only by voting in advance, so called advance voting (postal voting) in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations.

A special form shall be used for advance voting. The form is available on www.leovegasgroup.com. A shareholder who is exercising its voting right through advance voting do not need to notify the Company of its attendance to the general meeting. The advance voting form is considered as the notification of attendance to the general meeting.

The completed voting form must be at Euroclear Sweden AB’s disposal no later than on Monday 10 May 2021. The completed and signed form shall be sent by regular mail to Annual General Meeting, LeoVegas AB (publ), c/o Euroclear Sweden AB, Box 191, 101 23 Stockholm or by e-mail to [email protected]. The completed form must be available to Euroclear Sweden AB no later than 10 May 2021. Shareholders who are physical persons may also, on or before 10 May 2021, cast an advance vote electronically via verification with BankID on Euroclear’s website https://anmalan.vpc.se/EuroclearProxy.

The shareholder may not provide special instructions or conditions in the voting form. If so, the vote is invalid.Further instructions and conditions is included in the form for advance voting and at https://anmalan.vpc.se/EuroclearProxy.

Proposed agenda:

  1. Opening of the meeting and election of the chairman of the general meeting
  2. Preparation and approval of voting list
  3. Election of one person to certify the minutes
  4. Determination of whether the general meeting has been duly convened
  5. Approval of the agenda
  6. Presentation of the annual report and audit report and the group annual report and group audit report
  7. Resolutions regarding:
    a.       adoption of income statement and balance sheet and group income statement and group balance sheet;
    b.       appropriation of the Company’s profit or loss in accordance with the adopted balance sheet; and
    c.        discharge of liability for the directors and the managing director
  8. Determination of remuneration to the board of directors and the auditors
  9. Election of the board of directors and the auditors
  10. Election of the chairman of board of directors 
  11. Resolution regarding adoption of principles for the nomination committee
  12. Resolution regarding warrant program and issue of warrants 2021/2024 
    a.       Issue of warrants to the Subsidiary 2021/2024
    b.       Approval of transfer of warrants
    c.        Further information regarding the warrant program
  13. Resolution regarding authorising the board of directors to decide on repurchase and transfer of own shares
  14. Resolution regarding authorising the board of directors to decide on new issue of shares
  15. Submission of remuneration report for approval
  16. Closing of the meeting

Proposals for resolutions:

Item 1: Opening of the meeting and election of chairman of the general meeting

The nomination committee proposes that Carl Svernlöv, attorney at law, Baker & McKenzie Advokatbyrå, is appointed as chairman of the general meeting, or, in his absence, the person appointed by him.

Item 2: Preparation and approval of voting list

The voting list proposed for approval by the general meeting is the voting list established by Euroclear, based on the Annual General Meeting share register and incoming postal votes, and as verified by the person elected to certify the minutes.

Item 3: Election of one person to certify the minutes

The Board of Directors proposes that Ian Gulam, LL.M., at Baker & McKenzie Advokatbyrå, or if he is prevented, the person assigned by the Board of Directors, to person to verify the minutes of the meeting. The task also includes checking the voting list and that incoming postal votes are correctly reflected in the meeting minutes.

Item 7b): Appropriation of the Company’s profit or loss in accordance with the adopted balance sheet

The board of directors proposes that SEK 1.60 per share is distributed to the shareholders as dividend, in total SEK 160,290,602. The dividend is proposed to be distributed over four times with SEK 0.40 per share.   

1

11 May 2021

14 May 2021

19 May 2021

0.4

2

5 July 2021

7 July 2021

12 July 2021

0.4

3

5 October 2021

7 October 2021

12 October 2021

0.4

4

4 January 2022

7 January 2022

12 January 2022

0.4

Items 8-10: Determination of remuneration to the board of directors and the auditors, election of the board of directors and the auditors and election of the chairman of board of directors

The nomination committee proposes that the board shall consist of seven directors. The nomination committee further proposes that the number of auditors shall be one registered accounting firm.

The nomination committee proposes that the remuneration is to be not more than SEK 3,000,000 in total, including remuneration for committee work (SEK 2,800,000 previous year), and shall be paid to the board of directors and the members of the established committees in the following amounts:

  • SEK 325,000 for each of the non-employed directors and SEK 650,000 to the chairman provided that the chair is not an employee;
  • SEK 50,000 for each of the non-employed members of the remuneration committee and SEK 100,000 to the chairman of the committee who is not also an employee; and
  • SEK 50,000) for each of the non-employed members of the audit committee and SEK 100,000 to the chairman of the committee who is not also an employee.

The nomination committee proposes that the auditor shall be entitled to a fee in accordance with approved invoice.

The nomination committee proposes the re-election of the current directors Per Norman, Anna Frick, Fredrik Rüden, Mathias Hallberg, Carl Larsson, Torsten Söderberg and Hélène Westholm. It is also proposed to re-elect Per Norman as the chairman of the board.

The nomination committee further proposes the re-election of the registered audit firm PricewaterhouseCoopers AB as the company’s auditor for a period up until the end of the next annual general meeting. PricewaterhouseCoopers AB has announced its appointment of Aleksander Lyckow as main responsible auditor.

Independence in accordance with the Swedish Corporate Governance Code

After an assessment of the proposed directors’ independence the nomination committee has found that their proposal for the composition of the board of directors of the company fulfills the requirements stipulated in the Swedish Corporate Governance Code. All proposed directors are considered independent to the company, the management of the company and the company’s major shareholders.

Further information regarding the directors proposed for re-election is available at the company’s website www.leovegasgroup.com and in the annual report for 2020.

Item 11: Resolution regarding adoption of principles for the nomination committee

The nomination committee proposes that the following principles for the nomination committee are adopted.

Role of the nomination committee

The Company shall have a nomination committee with the task of preparing and proposing decisions to the shareholders’ meetings on electoral and remuneration issues and, where applicable, procedural issues for the appointment of the subsequent nomination committee. The nomination committee is to propose:

  • the chairman of the annual general meeting;
  • candidates for the post of chairman and other directors of the board;
  • fees and other remuneration for board work to each director;
  • fees to members of committees within the board;
  • election and remuneration of the Company auditor; and
  • principles for the nomination committee.

The nomination committee shall in its assessment of the evaluation of the board an in its proposal in particular take into consideration the requirement of diversity and breadth on the board and strive for equal gender distribution. Regardless of how they have been appointed, the members of the nomination committee are to promote the interests of all shareholders of the Company.

Members of the nomination committee

The nomination committee, which is to be appointed for the time until a new nomination committee has been appointed, shall consist of five members, of whom four shall be nominated by the Company’s four largest shareholders with respect to voting power and the fifth shall be the chairman of the board. The chairman of the board shall as soon as reasonably practicable after the end of the third quarter, in an adequate manner, contact the four owner registered largest shareholders, with respect to voting powers, according to the share register kept by Euroclear Sweden AB at that time and request that they, taken into consideration the circumstances, within reasonable time which cannot exceed 30 days, in writing to the nomination committee nominate that person whom the shareholder wishes to appoint as member of the nomination committee. If any of the four largest shareholders wish not to exercise their right to appoint a member of the nomination committee, the next shareholder in consecutive order shall be entitled to appoint a member of the nomination committee. In the case that several shareholders abstain their right to appoint a member of the nomination committee, the chairman of the board shall not be required to contact more than eight shareholders, unless it is necessary in order to obtain a nomination committee consisting of a minimum of four members.

Unless otherwise agreed between the members, the chairman of the nomination committee shall be nominated by the largest shareholder. A member of the board shall never be the chairman of the nomination committee.

If a shareholder who has appointed a member of the nomination committee during the year ceases to be one of the Company’s four largest shareholders, the member appointed of such shareholder shall resign from the nomination committee. Instead, a new shareholder among the four largest shareholders shall be entitled to independently and in its sole discretion appoint a member of the nomination committee. However, no marginal changes in shareholding and no changes in shareholding which occur later than two months prior to the annual general meeting shall lead to a change in the composition of the nomination committee, unless there are exceptional reasons.

If a member of the nomination committee resigns before the nomination committee has completed its assignment, for reasons other than set out in the paragraph above, the shareholder who has appointed by such member shall be entitled to independently and in its sole discretion appoint a replacement member. If the chairman of the board resigns from the board, his/her successor shall replace the chairman of the board also on the nomination committee.

A change in the composition of the nomination committee shall be published immediately.

Announcement of the nomination committee members

The chairman of the board shall ensure that the names of the members of the nomination committee, together with the names of the shareholders they have been nominated by, are published on the Company’s website no later than six months before the annual general meeting.

If a member leaves the nomination committee during the year, or if a new member is appointed, the nomination committee shall ensure that such information, including the corresponding information about the new nomination committee member, is published on the website.

Shareholders’ rights to submit proposals to the nomination committee

Shareholders shall be entitled to propose board members for consideration by the nomination committee. The nomination committee shall provide the Company with information on how shareholders may submit recommendations to the nomination committee. Such information shall be announced on the Company’s website.

The chairman of the board of directors shall, as part of the work of the nomination committee, keep the nomination committee informed about the work of the board of directors, the need for particular qualifications and competences, etc., which may be of importance for the work of the nomination committee.

The nomination committee’s proposals, work and fees

When preparing its proposals, the nomination committee shall take into account that the board of directors is to have a composition appropriate to the Company’s operations, phase of development and other relevant circumstances. The directors shall collectively exhibit diversity and breadth of qualifications, experience and background. The nomination committee shall further strive for equal gender distribution.

The nomination committee shall provide the Company with its proposals for board members in such time that the Company can present the proposals in the notice of the shareholders’ meeting where an election is to take place.

When the notice of the shareholders’ meeting is issued, the nomination committee shall issue a statement on the Company’s website explaining its proposals regarding the composition of the board of directors. The nomination committee shall in particular explain its proposal against the background of the requirement to strive for an equal gender distribution. The statement is also to include an account of how the nomination committee has conducted its work and a description of the diversity policy applied by the nomination committee in its work. In case a resigning managing director is nominated for the position of chairman of the board of directors, the nomination committee shall specifically explain the reasons for such proposal.

The nomination committee shall ensure that the following information on candidates nominated for election or re-election to the board of directors is posted on the Company’s website at the latest when the notice to the shareholders’ meeting is issued:

  • year of birth, principal education and work experience;
  • any work performed for the Company and other significant professional commitments;
  • any holdings of shares and other financial instruments in the Company owned by the candidate or the candidate’s related natural or legal persons;
  • whether the nomination committee deems the candidate to be independent from the Company and its executive management, as well as of the major shareholders in the Company. If the committee considers a candidate independent regardless of the existence of such circumstances which, according to the criteria of the Swedish Code of Corporate Governance, may give cause to consider the candidate not independent, the nomination committee shall explain its proposal; and
  • in the case of re-election, the year that the person was first elected to the board.

When appointing a new auditor the nomination committee is also to present proposals on the election and remuneration of the statutory auditor. The nomination committee’s proposal to the shareholders’ meeting on the election of the auditor is to include the audit committee’s recommendation (or that of the board of directors if it does not have an audit committee). If the proposal differs from the alternative preferred by the audit committee, the reasons for not following the committee’s recommendation are to be stated in the proposal. The auditor or auditors proposed by the nomination committee must have participated in the audit committee’s selection process if the company is obliged to have such a procedure.

Account of the work of the nomination committee

All members of the nomination committee, where possible, and as a minimum one of the members, shall be present at the annual general meeting.

The nomination committee shall at the annual general meeting, or other shareholders’ meetings where an election is to be held, give an account of how it has conducted its work and explain its proposals against the background of what is provided about the composition of the board in accordance with the above. The nomination committee shall in particular explain its proposal against the background of the requirement in accordance with above to strive for an equal gender distribution.

Fees and Costs

The Company shall bear all reasonable costs associated with the work of the nomination committee. Where necessary, the nomination committee may engage external consultants to assist in finding candidates with the relevant experience, and the Company shall bear the costs for such consultants. The Company shall also provide the nomination committee with the human resources needed to support the nomination committee’s work.

Item 12: Resolution regarding warrant programme through issuance of warrants 2021/2024

The board of directors of the Company proposes that the annual general meeting resolves to implement an incentive program through issuance of warrants in accordance with below.

Background and purpose

The purpose of the proposal, as of previous incentive programs, is to establish conditions to recruit and maintain qualified personnel in the company group and increase the motivation of the participants. The board of directors finds that it is in all shareholders’ interest that current and future senior executives, other employees and other key persons have a long term interest in developing a high value of the Company’s share. A long term ownership engagement is expected to stimulate an increased interest for the business and result in a whole as well as to increase the motivation for the participants and to create a common interest for the Company’s shareholders and the participant.

A. Issue of warrants 2021/2024

The Board of Directors proposes that the AGM resolves to issue of a maximum of 1,000,000 warrants, entailing an increase in the share capital upon full exercise by a maximum of EUR 12,000.01. The following terms shall apply to the issuance:

  1. The right to subscribe for the warrants shall, with deviation from the shareholders’ preferential rights, be given to the indirectly wholly owned subsidiary Gears of Leo AB, reg. no. 556939-6459 (the “Subsidiary”), with the right and obligation to transfer the warrants to employees within the group as per below.
  2. Oversubscription may not take place.
  3. The purpose for deviation from the shareholders’ preferential right is to implement an incentive programme whereby employees, through a personal investment, will participate and contribute in a positive development in the value of the Company’s shares during the period that the proposed programme covers, and to help the group to maintain and recruit qualified and engaged employees.
  4. The warrants shall be issued without any consideration.
  5. Subscription of the warrants shall take place not later than the day after the AGM.
  6. The board of directors has the right to extend the subscription period.
  7. Each warrant entitles to subscription of one new share in the Company. Subscription of new shares shall take place during the period commencing on 1 June 2024 up to and including 30 June 2024, or the earlier or later date as set out by the terms of the warrants in item 11 below. 
  8. Any share premium shall be transferred to the unrestricted premium reserve.
  9. The subscription price per share shall correspond to 130 percent of the volume-weighted average price according to the Nasdaq OMX Stockholm official price list for the share for the ten (10) days trading period immediately after the record date for the first instalment of ordinary dividends decided at the AGM 2021. The record date is proposed to be on 14 May 2021, which means that said period of ten trading days immediately after the record date will be 17 May 2021 up to and including 28 May 2021.
  10. The shares subscribed for by exercise of the warrants shall carry entitlement to participate in dividends for the first time on the next record date for dividends which occurs after subscription is effected.
  11. Warrants held by the Subsidiary that are not transferred as per below or that are repurchased from participants shall be cancelled after a decision by the Company’s board of directors. Cancellation shall be reported to the Swedish Companies Registration Office for registration.
  12. Other terms and conditions for the warrants are set out in the complete terms and conditions for series 2021/2024, which will be published on the Company’s website no later than three weeks prior to the meeting.

B: Approval of transfers of warrants

The board of directors proposes that the AGM resolves to approve that the Subsidiary transfers the warrants in accordance with the following terms.

The right to acquire warrants from the Subsidiary shall be given to a maximum of 60 persons from the group management, senior executives and key employees selected by the board of directors of the Company (the “Participants“).

The board of directors of the Company will not participate in the programme.   

1. Initially, each Participant will be offered to acquire warrants in accordance with the table set out below. For cases where one or more Participant do not acquire their full allotment, the Subsidiary has the opportunity to offer other Participants to acquire the remaining warrants. Such right shall primarily be given to Participants in Category A, secondarily to Participants in Category B, and thirdly to Participants in Category C.

                                    Category

                                    Number of Participants

                                    Number of warrants per Participant

                                    Total number of warrants

Group Management (“Category A”)

Maximum 10

40,000-125,000

400,000-1,000,000

Senior executives (“Category B”)

Maximum 40

15,000-30,000

300,000-800,000

Other key persons (“Category C”)

Maximum 40

5,000-15,000

125,000-400,000

2. The warrants shall be transferred on market terms. The preliminary market value has been established based on a calculated market value for the warrants, applying the Black & Scholes valuation model calculated by Svalner Skatt & Transaktion.                                                
The preliminary value is calculated to SEK 4.21 per warrant based on a share price of SEK 50.70, a subscription price per share of SEK 65,90, a term of three (3) years, a risk free interest rate of 38.00 percent and a volatility of -0.30 percent. The valuation is further based on an assumption of dividends of 3.90 percent per year.                                               
The final valuation of the warrants takes place in connection with the Participants’s acquisition of the warrants and will be based on market conditions at that time

3. In other respects, the warrants shall be subject to market terms including a right for the Company and the Subsidiary to repurchase warrants if a Participant’s employment with the Company ends or if the Participant wishes to transfer its Warrants to a third party.

4. Transfers to Participants require that the acquisition of warrants can be lawfully made and that this can be done with what the board of directors deems to be a reasonable administrative and economic effort.

5. Application to acquire warrants shall be made by 31 May 2021 at the latest. However, the Company’s board of directors shall have the right to extend the application period for acquisitions.

C: More detailed information about the warrant programme

  1. Dilution- Assuming full subscription and exercise of all warrants offered, 1,000,000 new shares can be issued, corresponding to dilution of approximately 1.0% of the total number of existing shares and votes in the Company, but with reservation for the recalculation of the number of shares that each warrant entitles to subscribe for that may take place as a result of certain issues, etc.            
  2. Costs and effects on key figures, etc. – The Company’s earnings per share will not be affected by the issue, since the warrants’ strike price exceeds the current market value of the shares at the time of the issue. The Company’s future earnings per share may be affected by the potential dilutive effect of the warrants in the event the Company reports a positive result and the strike price is lower than the market value. The warrants will be transferred at market value, which means that no taxable benefit value will arise and thus no social fees for the Company. The warrant programme will give rise to certain, limited costs in the form of external consulting fees and administration of the warrant programme.
  3. Calculation of market value – The preliminary market value has been established based on a calculated market value for the warrants, applying the Black & Scholes valuation model calculated by Svalner Skatt & Transaktion. 
  4. Drafting and preparations for the warrant programme  The warrant programme has been prepared by the board of directors and members of the group management and external advisors and in accordance with guidelines for remuneration to senior executives adopted by the AGM 2020 as ell in accordance with guidelines from the remuneration committee, and in consultations with major shareholders. The board of directors has thereafter decided to submit this proposal to the AGM. Apart from the executives who have participated in the drafting of this matter as per instructions from the Board of Directors, no employee who may be included in the programme has participated in the drafting of the terms.           
  5. Other share-based incentive programmes, etc.- For a description of the Company’s other share-based incentive programmes, please refer to the 2020 Annual Report and the Company’s website. No other share-based incentive programmes are in effect.
  6. The background and rationale for the proposal – The Board of Directors wishes to implement an incentive programme whereby employees, through a personal investment, will participate and contribute in a positive development in the value of the Company’s shares during the period that the proposed programme covers, and to help the group to maintain and recruit qualified and engaged employees.
  7.  Authorisations and decision-making rules                                               
    The AGM assigns the board of directors to execute the decision according to point B above.                                               
    The board of directors, or the party designated by the board of directors, is authorised to make such minor adjustments that are necessary for the decision’s registration with the Swedish Companies Registration Office and Euroclear Sweden AB.                                               
    The AGM’s resolution in accordance with Item 12 A and 12 B shall be considered as one decision. The AGM’s resolution on this point is valid only if approved by shareholders with at least nine-tenths (9/10) of the votes and shares represented at the AGM.                                               
    The resolution on the transfer of the warrants shall also be approved by a general meeting of the Subsidiary.

Item 13: Resolution regarding authorising the board of directors to decide on repurchase and transfer of own shares

The Board of Directors proposes that the Annual General Meeting resolves to authorise the Board of Directors to decide on purchases of the company’s own shares in accordance with the following, main terms:

  1. Share repurchases may be made only on Nasdaq Stockholm or any other regulated market.
  2. The authorisation may be exercised on one or more occasions before the 2022 Annual General Meeting.
  3. The maximum number of own shares that may be repurchased so that the company’s holding of shares at any given time does not exceed 10% of the total number of shares in the company.
  4. Repurchases of the company’s own shares on Nasdaq Stockholm may only be made at a price within the range of the highest purchase price and lowest selling price at any given time.
  5. Payment for the shares shall be made in cash.

In addition, the Board of Directors proposes that the Annual General Meeting resolves to authorise the Board of Directors to decide on transfers of own shares, with or without deviation from the shareholders’ preferential rights, in accordance with the following, main terms:

  1. Transfers may be made on (i) Nasdaq Stockholm or (ii) outside of Nasdaq Stockholm in connection with acquisitions of companies, operations or assets.
  2. The authorisation may be exercised on one or more occasions before the 2022 Annual General Meeting.
  3. The maximum number of shares that may be transferred corresponds to the number of shares held by the company at the point in time of the Board of Directors’ decision on the transfer.
  4. Transfers of shares on Nasdaq Stockholm may only be made at a price within the range of the highest purchase price and lowest selling price at any given time. For transfers outside of Nasdaq Stockholm, the price shall be set so that the transfer is made at market terms.
  5. Payment for transferred shares may be made in cash, through in-kind payment, or through set-off against claims with the company.

The purpose of the authorisations is to give the Board of Directors greater scope to act and the opportunity to adapt and improve the company’s capital structure and thereby create further shareholder value, and take advantage of any attractive acquisition opportunities.

The Board of Directors shall have the right to decide on other terms for repurchases and transfers of own shares in accordance with its authorisation. The Board of Directors also has the right to authorise the Chairman of the Board, the Group CEO, or the person designated by the Board to make such minor adjustments that may be necessary in connection with the execution of the Board’s decision to repurchase and transfer shares.

A valid resolution in favour of the Board’s proposal requires the approval of shareholders with at least two-thirds of the votes and shares represented at the Annual General Meeting.

Item 14: Resolution regarding authorising the board of directors to decide on new issue of shares

The Board of Directors of the Company proposes that the Annual General Meeting authorises the Board of Directors, on one or more occasions, during the time up until the next Annual General Meeting, to decide to increase the company’s share capital through a new issue of shares to such extent that it corresponds to a dilution of a maximum of 10% of the number of shares outstanding at the time of the Annual General Meeting calculated after full exercise of the issue authorisation now proposed.

A new issue of shares may be carried out with or without deviation from the shareholders’ preferential rights. Shares issued with deviation from the shareholders’ preferential rights shall be issued at market terms. The Board of Directors shall have the right to decide on other terms for the issue. Payment may be made against cash payment, in-kind payment for through set-off against claims with the company. If the Board of Directors finds it suitable in order to enable delivery of shares in connection with a share issuance as set out above it may be made at a subscription price corresponding to the shares quota value.

The purpose of the authorisation is to give the Board of Directors greater scope to act and the opportunity to adapt and improve the company’s capital structure and thereby create further shareholder value, and take advantage of any attractive acquisition opportunities.

The Chairman of the Board, the Group CEO or the person designated by the Board of Directors shall have the right to make such minor adjustments in the decision that may be necessary for registration of the decision with the Swedish Companies Registration Office.

A valid resolution in favour of the Board’s proposal above requires the approval of shareholders with at least two-thirds of the votes and shares represented at the Annual General Meeting.

Number of shares and votes

The total number of shares in the Company as of the date hereof amounts to 101,652,970 shares, with a corresponding number of votes. The Company holds 1,471,344 own shares.

Further information

Copies of accounts, audit report, auditor statement regarding guidelines for remuneration to the senior executives, proxy form, complete proposals and other documents that shall be available in accordance with the Swedish Companies Act are available at the Company at Luntmakargatan 18 in Stockholm and at the Company’s website www.leovegasgroup.com, at least three weeks in advance of the annual general meeting and will be sent to shareholders who request it and provide their e-mail or postal address. The remuneration report and a statement on the nomination committee’s proposal regarding the board of directors is available on the Company’s web site www.leovegasgroup.com as from today and will be sent to shareholders who request this report and provide their e-mail or postal address.

The board of directors and the managing director shall, if any shareholder so requests and the board of directors considers that it can be done without material harm to the Company, provide information at the general meeting on matters that may affect the assessment of an item on the agenda or the Company’s financial information. Such duty to provide information applies also to the Company’s relation to other group companies, the consolidated accounts and such circumstances regarding subsidiaries as specified in the foregoing sentence. A request for such information shall be received by the Company in writing no later than ten calendar days prior to the meeting, i.e., 1 May 2021 by post to the Company’s LeoVegas AB (publ), Attn: IR, Luntmakargatan 18, 111 37 Stockholm or by e-mail to [email protected]. The information will be made available at the Company’s website, www.leovegasgroup.com and at the head office no later than on 6 May 2021. The information will also be sent, within the same period of time, to any shareholder who so has requested and who has stated its e-mail or postal address.

Processing of personal data

For information on how personal data is processed in relation the meeting, see the Privacy notice available on Euroclear Sweden AB’s website: https://www.euroclear.com/about/en/regulatorylandscape/Data.html 

Stockholm in April 2021

LeoVegas AB (publ)

The board of directors

For further information, please contact:

Gustaf Hagman, Group CEO

+46 (0) 8 410 367 66, [email protected]

Philip Doftvik, Director of Investor Relations and Corporate Finance

+46 73 512 07 20, [email protected]

Per Norman, Chairman of the board

+46 (0) 8 410 367 66, [email protected]

about leovegas mobile gaming group: 

LeoVegas vision and position is “King of Casino”. The global group LeoVegas Mobile Gaming Group offers games on Casino, Live Casino, Bingo and Sport. The parent company LeoVegas AB (publ.) is located in Sweden and its operations are mainly located in Malta. The company’s shares are listed on Nasdaq Stockholm. www.leovegasgroup.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/leovegas-mobile-gaming-group/r/notice-of-annual-general-meeting-in-leovegas-ab–publ-,c3320624

The following files are available for download:

https://mb.cision.com/Main/17434/3320624/1397909.pdf

Notice of Annual General Meeting in LeoVegas AB (publ)

Cision View original content:http://www.prnewswire.com/news-releases/notice-of-annual-general-meeting-in-leovegas-ab-publ-301263787.html

SOURCE LeoVegas Mobile Gaming Group